Lipids & metabolic liver disease
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Pooled result · NASH resolutionResult — go to the resultRR for NASH resolution 2.48 95% CI 1.86–3.30Authors' conclusion
GLP-1 receptor agonists and SGLT-2 inhibitors have significant effects on reducing liver fat content and liver enzymes in NAFLD or NASH patients compared to placebo. GLP-1 receptor agonists were found to be superior to placebo in resolving NASH. SGLT-2 inhibitors were more effective than GLP-1 receptor agonists in reducing alanine aminotransferase and aspartate aminotransferase levels.
Study context
- Population
- Patients with MASLD or MASH (previously NAFLD and NASH); databases searched up to November 26, 202337 studies
- Comparison
- GLP-1 RA vs SGLT2i vs placebo
- Outcome
- NASH resolution
Methodological detailsPubmed, Embase, Cochrane Library and Web of Science searched up to November 26, 2023; two reviewers independently selected studies, extracted data and assessed risk of bias
- Pubmed, Embase, Cochrane Library and Web of Science searched up to November 26, 2023; two reviewers independently selected studies, extracted data and assessed risk of bias
Pooled result
As reported in the abstract
RR for NASH resolution
2.48
95% CI 1.86–3.30
GLP-1 receptor agonistsvs Placebo
RR for NASH resolution 2.48 (95% CI 1.86–3.30)
Further pooled results
Liver fat content and liver enzymes
- Both GLP-1 RA and SGLT2i superior to placebo in reducing liver fat content and liver enzyme levels
ALT and AST
- SGLT2i more effective than GLP-1 RA in reducing ALT and AST (network meta-analysis)
Anthropometric data (SUCRA ranking)
- GLP-1 RA and SGLT2i consistently ranked among the top 2 in reducing anthropometric data vs other included drugs
Original publication
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Endocr Pract. Published 17 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →